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The operational model of allosteric modulation and allosteric agonism [1-5] is being used 
routinely to assess the functional effects of allosteric modulators. Because the meaning 
of parameters and concepts often loses precision after extensive use, it may be timely to 
revise some particularities of the model to preclude possible misinterpretations. To do 
so, I will use the equation for the model as expressed in [4] 
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where Em is the maximum effect of the system; n, a parameter related with the slope of 
the curves; [A] and [B], the concentrations of the agonist A and the allosteric modulator 
B, respectively; τA and τB, the operational efficacies of A and B, respectively; KA and 
KB, the dissociation constants of A and B, respectively; and α and β, the cooperativity 
parameters governing binding and function, respectively. Values of α and β greater, 
equal and lower than 1 indicate positive, neutral and negative cooperativity, 
respectively. 
   I will not comment on all the parameters but only in a particular one the operational 
functional cooperativity β. The intrinsic efficacy of the receptor complexed with both 
the orthosteric agonist A and the allosteric compound B was defined [4] as εAB=εAβ, 
where εA denotes the intrinsic efficacy of A and β is a coupling factor that describes the 
ability of B to alter the signalling capacity of A when bound to the same receptor in a 
ternary ARB complex. This definition of of εAB, which does not include the intrinsic 
efficacy of B, is useful for data fitting because decreases the number of parameters of 
the model. However, it makes β not a pure cooperativity factor but a hybrid parameter 
embodying both intrinsic efficacy and functional cooperativity. To uncouple these 
properties, εAB was defined in an alternative mathematical model [6,7] as εAB= εAεBδ, 
where εB denotes the intrinsic efficacy of B and δ describes the activation cooperativity 
between A and B in the ARB complex (note that δ does not measure the influence of B 
upon A but the mutual cooperative effects between A and B). By making equal both 
expressions of εAB, we see that β=εBδ includes in its definition the intrinsic efficacy of 
the allosteric compound. The latter relationship shows that for a fixed δ effect those 
allosteric compounds displaying higher intrinsic efficacy will yield higher estimates of 
the β cooperativity parameter, if data are fitted with Equation 1. Remarkably, this was 
what it was found in a recent study on the functional activity of some mGlu4 positive 
allosteric modulators [8]. In this respect, a discussion on the correlation between the β 
parameter and the efficacy of allosteric ligands can be found in [9].  
   A reflection of the efficacy character that is included in β can be seen in the 
expression of the asymptotic maximum response of an agonist (Top) in the presence of 
a fixed concentration of an allosteric modulator. If we take the limit of the effect E as 
[A] increases in Equation 1 we obtain 
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   It is worth noting that τB is not included in the expression for Top effect, when it 
should logically appear. The reason for this is that the efficacy of the allosteric 
modulator B is implicitly included in the definition of β. 
   I will comment now a second matter. In an attempt to overcome the data fitting 
problems arising from the many parameters included in Equation 1, the simplified 
Equation 3 was proposed [10], 
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which was derived from Equation 1 under the following assumptions 
(i)   AKA   , and then AA KK[A]    
(ii)   AKAα   , and then   AA KKAα   
(iii) 1τ nA  , and then the location parameter of A in the absence of B in the 
operational model of agonism [11],     1τ2 KEC 1/nnA A50  , simplifies to   AA50 τ
KEC  . 
   All these assumptions relay on A being a full agonist. Additionally, assumption (ii) 
includes the property that the binding cooperativity α cannot be much greater than 1. It 
can be seen that Equation 3 reduces the number of parameters present in Equation 1 by 
considering jointly KA and τA through [EC50] and α and β through the composite 
cooperativity parameter αβ. 
   It is worth noting that because of the above assumptions, Equation 3 has a limitation 
in its use; that is, it is circumscribed to concentration-effect curves whose maximum 
responses (Top) do not differ from the maximum response of the system (Em).  
   If we calculate the asymptotic Top value from Equation 3 we have 
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which, contrary to Equation 2 and to the original formulation of the operational model 
[11], matches Em in all cases. Thus, Equation 3 cannot be used either for orthosteric 
compounds A displaying partial agonism or for allosteric compounds B increasing or 
decreasing the maximum response yielded by compounds A. 
   To briefly summarize, operational models of allosteric modulation and allosteric 
agonism [4,10] have proved useful for the quantification of the function of allosteric 
compounds; however, the pharmacological conditions imposed in some parameter 
definitions or the simplifications included in some equation derivations may lead to 
misleading conclusions if not used properly. Thus, caution is needed not to make 
interpretations from the models beyond the conditions and limitations inherent to them. 
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